Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Aug 2, 2023 · 10-Q · 33 days after period end · 0000950170-23-037125
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $238.99M | $211.24M | $141.84M | $111.34M |
| Net Income | -$23.94M | -$231.48M | -$81.41M | -$150.82M |
| EPS Diluted | -$0.27 | -$2.65 | -$1.02 | -$1.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 2, 2023 · 33 d after period end
